Study: Chinese COVID Shot May Offer Elderly Poor Protection, In Use In 50 Countries
AP News, July 23, 2021.
BUDAPEST, Hungary (AP) — A new study suggests that a Sinopharm vaccine offers poor protection from COVID-19 among the elderly, raising questions for dozens of countries that have given the Chinese company’s shots to their most vulnerable populations.
A survey of blood samples taken from 450 people in Hungary at least two weeks after their second Sinopharm dose found that 90% under 50 years old developed protective antibodies. But the percentage declined with age, and 50% of those over 80 had none.
The study by two Hungarian researchers was posted online this week but not yet reviewed by other scientists. Three outside experts said they had no problems with the methodology of the study of the vaccine developed by Sinopharm’s Beijing Institute of Biological Products.
“This is very, very worrying that these people, who are high-risk, have a poor antibody response,” said Jin Dong-yan, a Hong Kong University virologist who was not affiliated with the study. Antibody levels are not a direct measure of how protected a person is from COVID-19, but there is growing evidence that they are a good proxy. One expert cautioned that the choice of test kits could have limited the accuracy of the measurements...
Continued,
https://apnews.com/article/europe-middle-east-business-science-health-4b770731d5995e3bb49a1d8ec63febbd
- April 1, 2021, general practitioner Gyorgy Teleki vaccinates an elderly patient with the 2nd dose of COVID-19 vaccine produced by Chinese Sinopharm in Taplanszentkereszt, Hungary. A new study suggests that a Sinopharm vaccine offers poor protection from COVID-19 among the elderly, raising questions for dozens of countries that have given the Chinese company’s shots to their most vulnerable populations.
= new reply since forum marked as read
